TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer(Freeman Hospital), Nagy Habib(Imperial College London)Cell Reports MedicineApril 1, 202510.1016/j.xcrm.2025.102041Cited by 11SaveCiteExport RISWatch citationsRelated PapersFirst-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor|British Journal of Cancer|2020|76